1. Scrip
  2. >>R&D
  3. >>Clinical Trials

GSK’s Linerixibat GLISTENs In PBC Itching

 
• By Elizabeth Cairns

But differences in trial design means it is hard to handicap GSK’s product against Mirum’s volixibat.

Itch

GSK’s linerixibat has hit the endpoints in its Phase III study in cholestatic pruritus in primary biliary cholangitis (PBC), setting it up for approval in this niche indication. But a rival agent, Mirum Pharmaceuticals’ volixibat, posted Phase IIb data in June, and when the full linerixibat data come out they will have to be judged as good as or better than volixibat’s if GSK’s drug is to be successful. However, differences in how the trials’ endpoints will likely mean such a judgement tricky to make.

Key Takeaways
  • GSK’s linerixibat has succeeded in its Phase III study in cholestatic pruritus – chronic itching – in primary biliary cholangitis, setting it up to become the first therapy approved specifically for this indication.

PBC is a disease of the bile ducts that can cause liver damage, and like many autoimmune conditions mainly affects...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

Schrödinger Drops CDC7 Inhibitor SGR-2921 After Two Patient Deaths

 
• By Alaric DeArment

The drug is one of multiple candidates in the class that have been pulled from development, though it is not the company’s lead candidate.

Vedanta’s Live Bacteria Reach A Dead End In Ulcerative Colitis

 
• By Andrew McConaghie

The microbiome-based company’s trial of VE202 in ulcerative colitis has failed in Phase II, but its ongoing Phase III study in C difficile infection is more promising.

Xenon Nears Phase III Readout For Potential Epilepsy And Depression Blockbuster

 
• By Andrew McConaghie

Leading a field of rival potassium channel modulators, azetukalner will have a pivotal epilepsy readout early next year, with Phase III trials in depression and biopolar disorder also underway.

Another Day Another Win For Novartis’s Ianalumab – This Time In ITP

 
• By Aakash Babu

The Swiss drugmaker’s BAFF-R inhibitor and ADCC-mediated B-cell depletor candidate has chalked up another win in late-stage development, further strengthening its pipeline-in-a-product bid.

More from Therapy Areas

Vedanta’s Live Bacteria Reach A Dead End In Ulcerative Colitis

 
• By Andrew McConaghie

The microbiome-based company’s trial of VE202 in ulcerative colitis has failed in Phase II, but its ongoing Phase III study in C difficile infection is more promising.

Post-GLP-1 Patients Are Significant Opportunity, But Response Sees More

 
• By Alaric DeArment

The company will move ahead in testing RDX-002 among overweight and obese patients coming off GLP-1s, but the CEO said antipsychotic-induced weight gain could represent a multibillion-dollar market.

PureTech’s New Spin-Off Wants Partners For Pulmonary Fibrosis Drug

 
• By Andrew McConaghie

Deupirfenidone hit its Phase II endpoint but the program remains risky and PureTech’s new Celea Therapeutics will aim to pull in extra funding for its late-stage development.